TeraWulf (NASDAQ:WULF) reported $1.40 million in sales this quarter. This is a 67.07 percent decrease over sales of $4.25 million the same period last year.
NANOBIOTIX Announced New Data Presented at ASCO Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications
NANOBIOTIX (Euronext : NANO –– Nasdaq: NBTX – the ‘‘Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced the reporting of new data at the 2022 Annual Meeting of the American Society for Clinical Oncology (ASCO) featuring potential first-in-class radioenhancer NBTXR3 in combination wit
